EXPLORATORY ASSESSMENT OF THE EFFECTS OF CYCLO 3 ® FORT (Ruscus Extract, Hesperidin Methyl Chalcone, Ascorbic Acid) OR MICRONISED PURIFIED FLAVONOID FRACTION ON VASCULAR PARAMETERS AND BIOMARKERS IN WOMEN SUFFERING FROM CHRONIC VENOUS DISEASE (CEAP C2 OR C3), OVER 8 WEEKS

Inclusion Criteria

• •* Non-menopausal women aged from 18 to 50 years
• •* Symptomatic Primary chronic disorder C2 or C3 of advanced CEAP
• •* Regular menstrual cycle
• •* Use an efficient method of contraception
• •* Having signed her written informed
• •* Superficial and or deep venous thrombosis
• •* Venous insufficiency including history of deep venous thrombosis, post thrombotic syndrome, venous dysplasia, compressive syndrome
• •* History of venous strapping or phlebotomy/ surgery of the evaluated leg
• •* Sclerosing injection within 6 month before inclusion
• •* Oedema from other etiology
• •* Paresthesia, cramps of the lower limbs from other origin 2.2 Related to treatment:
• •* Hypersensitivity, allergy or intolerance to study drugs
• •* Iron storage disorder
• •* Intake of venotonic treatment (oral or topic) ,triptan ,diuretics ,calcium blockers, beta blockers, ACE inhibitors, angiotensine II inhibitors, vasodilatators and/or vasoconstrictors within 1 month before inclusion
• •* Intake of NSAID,corticosteroids,ergotamine, dihydroergotamine or any ergot alkaloids,vitamin C nutraceutical or phytotherapy products with potential venotonic effect within 2 weeks before inclusion 2.3 Related to the population:
• •* History of diabetes
• •* BMI≥ 30
• •* Grade V and VI on Fitzpatrick classification